New and Improved Treatments for Respiratory Diseases
KAER™ Biotherapeutics provides new treatments for respiratory diseases through the inhalation of therapeutic aerosols using its proprietary SUPRAER™ technology. KAER’s technology delivers fine particle aerosols generated from viscous solutions of high molecular weight drugs and suspensions. It can also be used to deliver high concentrations of sparsely soluble compounds. These inhaled therapeutics are delivered at a preselected size and at high dose rates, minimizing treatment times and improving clinical outcomes. KAER is developing aerosolized surfactant for the treatment of acute respiratory distress and works with pharmaceutical companies to deliver their proprietary agents. The company has a worldwide intellectual property portfolio (9 issued and 10 pending patents) for the generation, processing and delivery of aerosols for respiratory ailments.
KAER™provides services and devices for the generation and delivery of respirable aerosols. KAER addresses the needs of the biopharmaceutical and toxicological industries.
KAER’s SUPRAER™is a patented new class of aerosol delivery system. In this system, a large liquid aerosol is generated with a low-shear nozzle, dried, concentrated and delivered on demand. The dose rates are 5 to 30 times higher than current nebulizer technologies. SUPRAER extends the range of molecule, nanoparticles and organelles that can be aerosolized to form fine particle aerosols. These include, antibodies, antibody drug conjugates, fusion proteins, surfactants, oligonucleotides, cellular organelles, viruses and multi-walled carbon nanotubes (MWCNT's). KAER’s proprietary aerosol generation technologies are also applicable to the generation of aerosols of cells and cellular organelles. SUPRAER can also be used to generate nanoparticles and non-flammable vapors.
In recognition of the superiority of SUPRAER’s technology over those from the top competitive companies, together with its importance and impact on drug delivery, Frost and Sullivan awarded KAER Biotherapeutics their 2012 North American Technology Innovation Award for Aerosol Drug Delivery
Treatment of Lung Diseases by Aerosol Inhalation
ARDS and Need for a Viable Surfactant Treatment: Acute respiratory distress syndrome (ARDS) afflicts 10% of patients in intensive care (>200,000) with 40-60% mortality. Within 48 hours of a precipitating insult, patients develop multifocal airway collapse, edema and hypoxemia; each caused or aggravated by defective surfactant and its continued inflammation-induced degradation. Present treatment consists of life support with low tidal volume ventilation. A viable aerosol surfactant replacement therapy would reduce surface tension, open atelectatic airways and collapsed alveoli, and decrease the effort of breathing while improving oxygenation. A new life-saving therapy is made possible by the combination of surfactant together with its delivery at high dose rates using a new class of aerosol delivery system, SUPRAER®. Repeated aerosol surfactant therapy would treat the initial surfactant abnormalities as well as its continued degradation, leading to improved life support and patient survival.
Lung diseases that are being treated or destined to be treated with biotherapeutics include cancer, obstructive lung disease, asthma, cystic fibrosis, pulmonary fibrosis and pneumonia. The IV route is most often chosen because of the delivery limitations of present aerosol delivery systems. Intravenous administration not only has considerable patient resistance, but its own attendant complications. Given the high molecular weight of many of these agents, large doses are often required to achieve acceptable therapeutics levels. The treatment of lung diseases with such large masses (tens to hundreds of milligrams) of biotherapeutic aerosols has presented formidable technical challenges. The introduction of SUPRAER™ fulfills this need. KAER utilizes this SUPRAER platform technology to form partnerships with pharma to deliver their biotherapeutic directly to the lungs.
Aerosol delivery via the respiratory tract is the preferred mode of administration for lung diseases. Intravenous administration may require 5 to 100 times the dose of that delivered directly to the lung via inhalation. The ability to rapidly deliver high doses of therapeutics to the lung via inhalation provides direct access to the target organ while markedly reducing the total dose of the agent, cost of therapy, as well as the potential for systemic side effects.
It is notable that development of biologic agents comprise half of drugs in the pharmaceutical pipeline. These biotherapeutics include, proteins,fusion proteins, peptides, surfactants, oligonucleotides, antibodies,antibody drug conjugates, plasmids, vaccines and liposomes. In addition, there are other agents and large unstable molecules in which large masses are required to be deposited in the lungs for effective therapeutic results. New therapies could included the aerosol delivery of stem cells and cellular organelles.
Copyright KAER Biotherapeutics Corporation. All Rights Reserved